Keywords: inflazyme, halts, development, ipl512, canada, pharmaceuticals, discontinue

Inflazyme halts development of IPL512,602

Article | 28 June 2004

Print This

Canada's Inflazyme Pharmaceuticals is to discontinue the development of its asthma candidate IPL512,602, as the drug failed to meet the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in